News & Events
Food allergies may be linked to more MS relapses
In a recent study, scientists have shown that people with MS who have food allergies are more…
Global MS Research Booster Award 2019 – Call for applications
The Global MS Research Booster Award provides funding for scientists who aim to identify the cause(s) of…
Global webcast on solving progressive MS: progress achieved and hope for the future
Building momentum for World MS Day 2019
The 'My Invisible MS' toolkit is now available online
Adventure in the face of diagnosis: new research supported by MS Australia
A new study supported by MS Australia suggests that adventure and challenge can help people manage an…
The next Atlas of MS is underway
MSIF’s Atlas of MS with new data on the number of people living with MS across the…
India’s bikers against MS
The MS Society of India celebrated India MS Day with a national bike rally. Learn more about…
Music legend Masta Ace: hip-hop, MS and getting creative
The UK MS Society met up with Brooklyn rapper and record producer Masta Ace to talk about…
European Medicines Agency reviews safety of alemtuzumab
EMA conducts safety review of alemtuzumab (Lemtrada)
Cladribine approved in US for people with active secondary progressive MS
FDA approves cladribine for people with relapsing forms of MS and active secondary progressive MS
Treatment licensed in US for people with active secondary progressive MS
FDA approves the drug Siponimod, to treat people with active secondary progressive MS
How different disease modifying therapies can delay progression
A new study examined different disease modifying therapies and their ability to slow the onset of secondary…